Tuesday, April 28, 2026, 12:00 PM–1:00 PM ET
Discover how next-day comprehensive genomic profiling (CGP) is possible with the Oncomine Comprehensive Assay Plus on the Genexus System—delivering both speed and accuracy.
Webinar presenters Jane Bayani, MHSc, PhD, Assistant Professor and Co-Director, Diagnostic Development, Ontario Institute for Cancer Research, Canada, and Nicola Normanno, MD, Scientific Director, IRCCS Romagnolo Institute for the Study of Tumors, Italy, and Morten Grauslund, PhD, Molecular Biologist, Department of Pathology, Rigshospitalet/Copenhagen University Hospital, Copenhagen, Denmark.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Thermo Fisher Scientific. For Research Use Only. Not for use in diagnostic applications.
Thursday, April 30, 2026, 11:00 AM–12:00 PM ET
Hear an expert discuss how Memorial Sloan Kettering Cancer Center (MSKCC) is utilizing
the oncoReveal® Nexus 21-gene panel to redefine turnaround time and actionable insights
in cancer care. Dr. Ewalt shares a perceptive look at the clinical need for rapid, front-line NGS sequencing, and how a unique, purpose built targeted NGS panel (Pillar Biosciences’ oncoReveal Nexus 21 gene Panel) was developed, validated and implemented clinically by Memorial Sloan Kettering Cancer Center (MSK-REACT) to complement their current comprehensive genomic profiling (CGP) approach.
Webinar presenter Mark Ewalt, MD, Associate Medical Director for Laboratory Operations for Diagnostic Molecular Pathology in the Molecular Diagnostics Service, Department of Pathology and Laboratory Medicine, MSKCC.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Pillar Biosciences.
Thursday, May 28, 2026, 1:00–2:00 PM ET
This session is designed to improve understanding and application of recent updates to synoptic pathology reporting protocols such as the latest Reporting Template for Reporting Results of Biomarker Testing of Specimens from Patients with Carcinoma of the Breast. These changes reflect evolving clinical guidelines that directly influence diagnostic accuracy and treatment selection in breast cancer care.
Webinar presenters Thaer Khoury, MD, FCAP, Chair, Pathology and Laboratory Medicine, Roswell Park Comprehensive Cancer Cente, and Colin Murphy, CEO of mTuitive.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
November 2016—Siemens Healthineers released a software upgrade for its RapidComm Data Management System version 6.0, an informatics solution to centrally manage in vitro diagnostics analyzers and operators at the point of care. In addition to the system’s enhanced productivity and performance features, RapidComm V6.0 now connects with POC cardiac devices.
November 2016—Aalto Bio Reagents, a developer and provider of raw materials to the in vitro diagnostics industry and to research laboratories worldwide, announced the availability of its Tri-Plex suite of proteins and antibodies, which include its Zika Virus primary Envelope and NS1 proteins plus Chikungunya E2 wild type, E1 mutant, and E1 wild type proteins, and a complete set of Dengue virus proteins for serotypes 1–4.
November 2016—nzo Life Sciences introduced its new line of in situ hybridization and immunohistochemistry reagents for use with Enzo’s Highdef chromogens in ISH and IHC applications.
November 2016—Mindray has received 510(k) clearance from the Food and Drug Administration to market and sell the Mindray BC-5390 Auto Hematology Analyzer. The Mindray BC-5390 analyzer is designed to meet the testing needs of mid-volume hematology laboratories while offering features commonly found on large-volume analyzers.
November 2016—Sarstedt offers low protein binding micro tubes in 0.5 mL, 1.5 mL, and 2.0 mL volumes. These tubes are designed to meet the requirements of protein analytics while maximizing protein recovery rates. The micro tubes are manufactured from a proprietary polypropylene with low protein binding properties and do not feature any potentially contaminating surface coating like silicone.
November 2016—Meridian Life Science released a new catalog that provides a detailed overview of the company’s cardiac and metabolic markers for assay development. Meridian’s top-performing cardiac and metabolic markers include Lp-PLA2, CRP, D-dimer, troponin, NT-proBNP, myoglobin, procalcitonin, FABP, PAPP-A, fibrinogen, sCD40L, MPO, NSE, and galectin-3.
November 2016—U.K.-based Arcis Biotechnology launched its Arcis DNA Blood Kit (IVD) for preparation of DNA from blood using a novel three-minute, two-step system.
October 2016—ET Healthcare presented two posters at the meeting. Data from the abstract “A whole blood high-sensitivity cardiac troponin assay for POCT” showed that the Pylon cTnl assay met the definition of a fourth-generation high-sensitivity cardiac troponin I assay, with less than 10 percent CV at the 99th percentile and detection in greater than 95 percent of the reference population.
October 2016—Telcor’s QML eLearning interface performs tasks vital to managing point-of-care-testing operators while storing recertification data, such as competency and samples performed together in the company’s QML software for CAP/CMS/JCAHO inspections.
October 2016—Waters Corp. showcased its newest IVD medical device for clinical laboratories, the Acquity UPLC I-Class/Xevo TQ-S micro IVD system. The Xevo TQ-XS is a high-performance tandem quadrupole instrument that aims to expand the scope of ultimate sensitivity analysis.
